Home / Health / Diabetes Drug ASC30 Completes US Phase II Trial
Diabetes Drug ASC30 Completes US Phase II Trial
27 Apr
Summary
- Ascletis Pharma's ASC30, an oral GLP-1 agonist, finished its US Phase II study.
- The trial evaluated safety, tolerability, and efficacy for type 2 diabetes.
- Topline results are anticipated in the third quarter of 2026.
Ascletis Pharma has announced the completion of subject enrollment in its 13-week US Phase II study for ASC30, an investigational oral small molecule GLP-1 receptor agonist aimed at treating type 2 diabetes mellitus (T2DM).
The multi-center, randomized, double-blind, placebo-controlled trial involved 100 participants across the United States. It was designed to evaluate the safety, tolerability, and efficacy of ASC30 tablets, with a primary endpoint measuring the mean change in HbA1c compared to a placebo after 13 weeks.
Secondary objectives included assessing changes in fasting blood glucose, body weight, and overall safety. Participants received daily doses of 40mg, 60mg, or 80mg of ASC30, or a placebo, with doses titrated weekly. Ascletis anticipates releasing topline results from this study in the third quarter of 2026.
Ascletis developed ASC30 internally, positioning it as a first-in-class investigational small molecule GLP-1R fully biased agonist. The drug is designed for convenient oral dosing and potential long-acting subcutaneous administration for obesity, diabetes, and other metabolic conditions. The company views the expansion into the diabetes market as a logical progression to showcase ASC30's potential best-in-class profile for a once-daily oral treatment.
